ITGAM and hepatocellular carcinoma: To understand the possible underlying mechanisms behind the efficient anti-HCC effect of Ad-ΔB/TRAIL+Ad-ΔB/IL-12 combination therapy, the expression level of three cellular markers; NK1.1-, CD11b-, CD31- positive cells, and the change in the intratumor microvascular density was examined by IHC.